FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/11/2022
Voltar para busca
Dado oficial do USPTO
BELMONITOR COV-2
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
07/11/2022
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10
Data de depósito
22/12/2020
Data de registro
24/05/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/05/2022
Última transação
24/05/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
01
Localização do titular
DE
Examinador
LOOK, JEFFREY
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "BelMonitor" in stylized letter with "BEL" in dark blue and "MONITOR" in light blue with "COV-2" in white letters inside a light blue rectangle beneath the letters "BEL".
Titulares e representantes
Titulares
R. B. (pessoa física)
PharmACT Holding AG
Representantes
Brian P. Gregg MCNEES WALLACE & NURICK
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Reagents for medical use; diagnostic chemical reagents for medical use; clinical medical reagents; clinical diagnostic reagents for medical purposes; enzymes for medical purposes with all of the foregoing for use in testing and diagnosing Sars-Cov-2 exposure; medical preparations and chemicals for pharmaceutical usefor use in the treatment and disagnosis of SARSCOV-2 or Covid-19; pharmaceutical preparations in strip form for the treatment of Covid-19; pharmaceutical preparations for the prevention of disorders of the endocrine system that may be affected by Covid-19; chemical preparations for testing blood for medical purposes to determine Sars-Cov-2 or Covid-19 exposure; chemical preparations for medical purposesfor the treatment of Covid-19; chemico-pharmaceutical preparations for the treatment of Covid-19; pharmaceutical preparations for the prevention of diseases of the metabolic systemin particularSars-Cov-2; in-vitro reagents for medical diagnostic purposes to determine exposure to Sars-Cov-2; chemical preparations for pharmaceutical purposesfor treatment of Covid-19; medical diagnostic test strips for testing for Covid-19 viral infection; diagnostic agents for medical use and diagnostic reagents for medical use in testing for Sars-Cov-2 exposure; medicated mouth spray for treating Covid-19 viral infections; pharmaceutical preparations for the prevention of disorders of the metabolic system related to Sars-Cov-2 exposure; pharmaceutical preparations for the treatment of Covid-19 viral infections; chemical preparations for use in DNA analysis for medical purposes related to diagnosing and treating Sars-Cov-2; biological reagents for medical diagnostic use for medical purposes related to diagnosing and treating Sars-Cov-2; diagnostic chemical reagents for medical use related to diagnosing and treating Sars-Cov-2
Classe 10
Genetic testing apparatus for medical purposes for diagnosing exposure to Sars-Cov-2; chromatogram analyzers for medical use; patient monitoring sensors and alarms; chromatographic instruments for medical use; tools for medical diagnosticsmedical ultrasound apparatusspirometerselectromagnetic medical diagnostic imaging apparatusmedical instruments for examining women's reproductive organsmedical instruments for use in performing biopsies; chromatographic apparatus for medical use; physical analyzers for medical usehematology analyzers for medical diagnostic usesbody composition analyzers for medical purposesskin moisture analyzers for medical purposesanalyzers for the analysis of body fluids; medical diagnostic saliva pads; immunoadsorption columns for medical diagnostic use; chromatographic columns for medical use; apparatus for blood monitoring for medical use; spittoons for medical purposes; all of the foregoing for use in diagnosing or treating Sars-Cov-2 infections
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
14/09/2022
XXCR
GENERIC MADRID TRANSACTION CREATED
14/09/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/08/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
24/05/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/02/2022
PUBO
PUBLISHED FOR OPPOSITION
22/02/2022
GPNX
NOTIFICATION PROCESSED BY IB
20/02/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/02/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/02/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/01/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/01/2022
RFNT
REFUSAL PROCESSED BY IB
01/08/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/07/2021
RFRR
REFUSAL PROCESSED BY MPU
14/07/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/07/2021
CNRT
NON-FINAL ACTION WRITTEN
12/07/2021
DOCK
ASSIGNED TO EXAMINER
07/07/2021
DOCK
ASSIGNED TO EXAMINER
28/06/2021
DOCK
ASSIGNED TO EXAMINER
18/06/2021
MAFR
APPLICATION FILING RECEIPT MAILED
12/03/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/03/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/03/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BELMONITOR COV-2 ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.